Adverse events in bedaquiline- and pretomanid-based regimens for drug-resistant tuberculosis from trial, implementation and pharmacovigilance studies
InfectologiaSobre o estudo
- Desenho
- Revisão sistemática
- Nível de evidência
- 1 · Evidência consolidada
- Revista
- British journal of clinical pharmacology
- Publicado em
- 12 mai 2026
- Citações
- 0
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Adverse events in bedaquiline- and pretomanid-based regimens for drug-resistant tuberculosis from trial, implementation and pharmacovigilance studies
Nisa Maria, Annisa Lazuardi Larasati, Indri Yuliani Hamdani, Parisa Aslani, Jan-Willem Alffenaar
Descritores MeSH
- Diarylquinolines
- Nitroimidazoles
- Tuberculosis, Multidrug-Resistant
- Antitubercular Agents
- Pharmacovigilance
- Clinical Trials as Topic
- Drug Therapy, Combination
- Humans
Veja também
Estudos relacionados
- Chinese guideline for the chemotherapy of multidrug-resistant/rifampicin-resistant tuberculosis (2026 edition)
- Executive Summary: Clinical Practice Guidelines on the Management of Resistant Tuberculosis of the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR) and the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC)
- Efficacy and safety of bedaquiline and delamanid in the treatment of drug-resistant tuberculosis in adults: A systematic review and meta-analysis
- A Pragmatic Trial of a 6-Month Strategy for Rifampicin-Resistant Tuberculosis